Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.81

€1.81

-2.690%
-0.05
-2.690%
€3.00
 
18.09.24 / Stuttgart Stock Exchange WKN: A3DWEE / Symbol: PULM / Name: Pulmatrix / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Pulmatrix Inc. Stock

We can see a decrease in the price for Pulmatrix Inc.. Compared to yesterday it has lost -€0.050 (-2.690%).
With 1 Sell predictions and 1 Buy predictions the community sentiment towards the Pulmatrix Inc. stock is not clear.
With a target price of 3 € there is a hugely positive potential of 65.75% for Pulmatrix Inc. compared to the current price of 1.81 €.
So far the community has only identified positive things for Pulmatrix Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Pulmatrix Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pulmatrix Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pulmatrix Inc. -2.690% 4.819% -1.136% -11.495% 6.227% -86.470% -88.574%
Evolus Inc -3.360% 8.824% 23.333% 70.115% 63.536% 120.896% -
Ardelyx Inc. -3.940% 7.242% 4.451% 29.696% -4.187% 390.088% 30.598%
Coherus Bioscien. 1.760% -24.782% -18.208% -79.734% -69.368% -93.792% -95.284%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financial health of Pulmatrix, symbolized as PULM in the Biotechnology & Medical Research sector, presents a mixed picture. While some aspects indicate growth potential, others reveal significant challenges that the company must address. A closer examination of Pulmatrix’s financial statements uncovers several strengths and weaknesses that can influence future performance.

Starting off with the positives, Pulmatrix has shown a notable quarterly revenue growth year-over-year of 2.926%. This is an encouraging sign in a competitive industry where innovation and expansion are crucial for survival. Additional strength lies in the company’s gross profit of $6,071,000, which indicates that the business is generating revenue that covers its production costs. Moreover, with a book value of $5.207, there’s a considerable asset foundation backing the company.

However, juxtaposing these positives are substantial concerns. The negative EBITDA of -$9,247,000 highlights ongoing operational inefficiencies and a serious monetary outflow that raises red flags about the sustainability of current practices. The persistently negative profit margin of -0.7573 and a return on assets of -0.177 suggest that the company is not effectively translating revenues into profits, leading to potential cash flow issues moving forward. Even more troubling is the return on equity (ROE) of -0.3845, revealing that shareholder equity is eroding rather than growing.

Comments

Prediction Buy
Perf. (%) -16.81%
Target price 9.154
Change
Ends at 15.08.24

Pulmatrix, Inc. (NASDAQ: PULM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for PULM provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 82.31%
Target price
Change
Ends at 13.01.20

Buy beendet
Show more

Buy Pulmatrix Inc
Show more